Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).

Citation

• de Souza, P. L., Wong, S., Sewak, S., Kotasek, D., Keam, B., Chung, J., . . . Mainwaring, P. N. (2018). Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).. Journal of Clinical Oncology, 36(6_suppl), 648. doi:10.1200/jco.2018.36.6_suppl.648

Digital Object Identifier (doi)

• 10.1200/jco.2018.36.6_suppl.648

Web Of Science Accession Number

Start Page

• 648

End Page

• 648

Volume

• 36

Issue

• 6_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2018

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• de Souza, P. L., Wong, S., Sewak, S., Kotasek, D., Keam, B., Chung, J., . . . Mainwaring, P. N. (2018). Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).. Journal of Clinical Oncology, 36(6_suppl), 648. doi:10.1200/jco.2018.36.6_suppl.648

Digital Object Identifier (doi)

• 10.1200/jco.2018.36.6_suppl.648

Web Of Science Accession Number

Start Page

• 648

End Page

• 648

Volume

• 36

Issue

• 6_suppl

Place Of Publication